Skip to main content
Clinical Trials/NCT01970332
NCT01970332CompletedNot Applicable

Mitochondrial Dysfunction, Oxidative Damage and Inflammation in Claudication

University of Nebraska1 site in 1 country220 target enrollmentStarted: September 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
220
Locations
1
Primary Endpoint
Leg biomechanics

Study Overview

Brief Summary

Intermittent claudication afflicts 5% of the US population older than 55 years of age and develops along with hardening of the arteries of the legs. Claudicating patients limp and can only walk very short distances because their legs hurt. This protocol evaluates the mechanisms that may produce the leg dysfunction of claudication and its successful completion can ultimately produce significant new diagnostic and treatment strategies for the care of claudicating patients.

Detailed Description

Claudication, defined as walking-induced leg discomfort and gait dysfunction relieved by rest, affects 5% of Americans over 55 years of age. Claudicating patients adopt sedentary lifestyles and cluster at the extreme low end of the physical activity spectrum, escalating risk for adverse health effects. The primary therapeutic goals for claudicating patients are restoration of leg function and prevention of disease progression. Current, rehabilitative interventions focus on inadequate blood flow as the only cause of claudication. Operative revascularization and/or exercise therapy are the principal conventional therapeutic modalities, providing only modest rehabilitative benefit. Applying biomechanical analysis to gait of claudicating patients, the investigators team has developed preliminary data indicating that blood flow is not the only mechanism producing the limb dysfunction of claudication. Several laboratories including the investigators own have demonstrated a myopathy, characterized by mitochondrial dysfunction, oxidative damage and inflammation, in leg skeletal muscle of claudicating patients. These conditions have not been quantified, comprehensively, in relation to claudication, and their association with severity of claudication is not known. The investigators hypothesis is that blood flow restriction is not a good predictor of limb dysfunction in claudication, whereas muscle mitochondrial dysfunction, oxidative damage and inflammation are strong predictors of limb dysfunction both at baseline and after conventional therapy with revascularization or supervised exercise. Under Aim #1, the investigators will acquire precise measurements of gastrocnemius mitochondrial function, oxidative damage and inflammation in claudicating patients, at the time of their initial presentation, and evaluate these measurements as predictors of objective measures of limb function and subjective measures of quality of life. Under Aims #2 and #3, the investigators will evaluate the effects of revascularization (Aim#2) and supervised exercise therapy (Aim#3) on mitochondrial dysfunction, oxidative damage and inflammation in claudicating gastrocnemius and on objective measures of limb function and subjective measures of quality of life. If the investigators hypothesis is correct, the work in Aim #2 will for the first time definitively demonstrate that blood flow restriction due to blockages in the arterial tree is not the only cause of claudication. The work under Aims #2 and #3 will determine whether revascularization or exercise therapy has a beneficial effect on the myopathy of claudicating muscle with associated improvement in limb function and quality of life. Finally, the proposed studies under Aims #1, #2 and #3 will provide quantitative modeling of a panel of mechanistic (bioenergetics, oxidative stress and inflammation) parameters as predictors of objective measurements of claudicating limb function and subjective measures of quality of life commonly used for clinical assessment. Measurements of gastrocnemius mitochondrial function, oxidative damage and inflammation may be useful tools that permit staging of disease for optimum intervention and evaluation of therapeutic interventions that specifically target these conditions, improving rehabilitative outcomes.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •a positive history of chronic claudication
  • •exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
  • •an ankle/brachial index < 0.90 at rest

Exclusion Criteria

  • •absence of Peripheral Arterial Disease (PAD)
  • •acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma
  • •exercise capacity limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology

Arms & Interventions

No Exercise Therapy or Revascularization operation

No Intervention

The patient is evaluated but no intervention

Revascularization Surgery

Experimental

The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)

Intervention: Supervised exercise therapy (Other)

Exercise Therapy

Experimental

The patient undergoes supervised exercise therapy for 6 months

Intervention: Revascularization Surgery (Procedure)

Outcomes

Primary Outcomes

Leg biomechanics

Time Frame: six months

Propulsion Impulse, Ankle plantarflexor torque, Ankle plantarflexor power and maximum isometric plantarflexion force

Quality of life Questionnaires

Time Frame: six months

Walking Impairment Questionnaire and the Medical Outcomes Study Short Form 36 Healthy Survey

Walking distances

Time Frame: six months

Initial Claudication Distance, Absolute Claudication Distance, 6-Minute Walking Distance

Leg hemodynamics

Time Frame: 6 months

Ankle Brachial Index

Secondary Outcomes

  • Myofiber Oxidative Damage(6 months)
  • Myofiber Morphology(6 months)
  • Myofiber Mitochondrial Function(6 months)
  • Muscle inflammation(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials